DCompany · Healthtech & Bio
deepull
Deepull is a Barcelona-based diagnostics company developing UllCORE, a fully automated molecular testing system that detects sepsis-causing pathogens and antibiotic resistance markers directly from whole blood in about an hour, without the need for blood culture. The company received FDA Breakthrough Device Designation in December 2024 and is a Series C-stage medtech scaleup founded by the team behind STAT-Dx (sold to QIAGEN in 2018).
Founded
2018
Founders
2
News
5
Rounds
4
Investors
11
SectorsDiagnostics, Medical Devices, Molecular Testing, Sepsis/Infectious Disease
Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing
Profile updated 3 Aug 2026
Founders
J
Jordi Carrera
Co-Founder & CEO
R
Rafel Bru Gibert
Co-Founder & CTO
—
Global models
No comparables on record yet.
Investors 11
AAliath Bioventures
AAlta Life Sciences
www.altals.com
AAsabys Partners
asabys.com
AAxis Participaciones Empresariales
www.axispart.com
CCDTI (Innvierte)
www.cdti.es
CColumbus Venture Partners
columbusvp.com
KKurma Partners
MMérieux Equity Partners
P
Panakès Partners
UUI Investissement
WWe Venture Capital
weventurecapital.com
Funding rounds 4
News & media 5
| Published | Article |
|---|---|
| 2026-05-07 |
Healthtech: 10 companies that raised the most in 2025 ↗
Tech.eu
|
| 2026-02-19 |
Catalonia hits record investment in health startups and scaleups and consolidates BioRegion as leading European hub for research and industry ↗
Biocat
|
| 2025-04-29 |
deepull raises $57m in Series C funds for advancing pathogen detection system ↗
Medical Device Network
|
| 2024-12-02 |
FDA grants breakthrough device designation to deepull's BSI test ↗
Medical Device Network
|
| 2024-04-25 |
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024 ↗
GlobeNewswire
|